Great attention is paid to SGLT2i in cancer patients with or without diabetes under anthracycline therapy due to their beneficial effects, including reduction of ferroptosis, reduction of lipid peroxidation, improvement of mitochondrial functions, activation of pAMPK, and reduction of the NLRP3-dependent pathway [58]. The gene discussed is NLRP3; the disease is diabetes mellitus.